Behavioural Intervention
Colon Cancer Screening Toolkit for Colorectal Cancer
Recruiting1 award2 criteria
Saint Louis, Missouri
This trial is testing a multilevel intervention to improve follow-up rates for positive fecal immunochemical tests (FITs), which are used to screen for colorectal cancer (CRC). The intervention is being implemented in a rural, underserved area in Southern Illinois.
Dietary Intervention
Diet Impact on Colon Cancer Risk
Recruiting1 award12 criteria
Chicago, Illinois
This trial studies how two different diets affect gut bacteria in African Americans at higher risk for colorectal cancer. One diet is high in red meat and fats, while the other is plant-based and low in fats. Researchers aim to see if these diets change gut bacteria to produce harmful substances that could increase cancer risk.
Behavioral Intervention
Physical Activity and Education for Colorectal Cancer
Recruiting1 award26 criteria
Detroit, Michigan
This trial is studying a physical activity program given together with health education materials to see how well it works compared with giving health education materials alone for patients who have undergone treatment for high-risk stage II or stage III colon cancer.
Behavioural Intervention
Physical Activity Program for Breast and Colon Cancer Survivors
Recruiting1 award
Winston-Salem, North Carolina
"This trial aims to see if using a physical activity index screener, exercise coaching, and self-monitoring can help breast or colon cancer patients increase physical activity and reduce time spent sitting or being inactive."
Popular Filters
Trials for Colorectal Cancer Patients
PD-1 Inhibitor
Dostarlimab for Colon Cancer
Recruiting2 awardsPhase 3
Tucson, Arizona
This trial is testing dostarlimab, a drug that helps the immune system fight cancer. It targets patients with a specific type of colon cancer that has certain genetic features and can be surgically removed. Dostarlimab works by helping the immune system recognize and destroy cancer cells.
Trials for Adenocarcinoma Patients
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET Scan for Cancer
Recruiting1 award7 criteria
Duarte, California
This trial uses a radioactive antibody to help detect cancer cells in patients with high levels of a protein called CEA. PET scans may help find and diagnose cancer that may not be detected by other methods.
MEK Inhibitor
AZD6244 + Chemotherapy for Advanced Cancer
Recruiting1 awardPhase 1
Detroit, Michigan
This study is evaluating whether a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with selected chemotherapies will be evaluated
Trials for Metastatic Patients
CDK4/6 Inhibitor
Palbociclib + Cetuximab for Colon Cancer
Recruiting1 awardPhase 2
Chapel Hill, North Carolina
This trial is testing a combination of two drugs, cetuximab and palbociclib, to treat patients with advanced colon cancer. The drugs work together to block cancer cell growth and division. The study focuses on patients whose cancer has specific protein characteristics and who have either not been treated with similar drugs before or have developed resistance after initial treatment.
Chemotherapy
Chemotherapy + Atezolizumab for Colon Cancer
Recruiting2 awardsPhase 3
Anchorage, Alaska
This trial is testing whether adding atezolizumab to standard chemotherapy works better than chemotherapy alone for patients with stage III colon cancer who have a specific genetic defect. The chemotherapy drugs aim to kill cancer cells, while atezolizumab helps the immune system attack the cancer. Researchers hope this combination will improve survival rates and quality of life for these patients.
PD-1 Inhibitor
Dostarlimab for Colon Cancer
Recruiting2 awardsPhase 2
Iowa City, Iowa
This trial is testing the immunotherapy drug dostarlimab in patients with Stage II and III colon cancer. The goal is to see if the drug can shrink the tumors enough to avoid surgery. Dostarlimab helps the immune system attack the cancer cells.
Histone Deacetylase Inhibitor
Combination Immunotherapy for Human Papillomavirus & Colorectal Cancer
Recruiting1 awardPhase 1 & 2
Bethesda, Maryland
This trial is testing a new combination drug treatment for people with metastatic HPV-associated cancers or microsatellite stable small bowel or colorectal cancer.
Trials for MSS Positive Patients
Checkpoint Inhibitor
Immunotherapy + Radiation for Colorectal and Lung Cancer
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is testing the side effects of two immunotherapies, durvalumab and tremelimumab, in combination with high or low-dose radiation therapy, in treating patients with metastatic colorectal or non-small cell lung cancer.
Cancer Vaccine
ATP128 + VSV-GP128 + BI 754091 for Colorectal Cancer
Recruiting1 awardPhase 1
Scottsdale, Arizona
This trial is assessing the safety and tolerability of the ATP128 vaccine when given alone or in combination with BI 754091. The trial will also assess the efficacy of the combination of ATP128 and VSV-GP128 when given in combination with BI 754091 in patients with microsatellite stable colorectal cancer.
Monoclonal Antibodies
Encorafenib + Cetuximab + Nivolumab for Colorectal Cancer
Recruiting1 awardPhase 1 & 2
Houston, Texas
This trial is testing a combination of drugs to treat patients with colorectal cancer that has spread and cannot be removed by surgery. The drugs work by blocking enzymes needed for cell growth and by helping the body's immune system attack the cancer.
Checkpoint Inhibitor
Regorafenib + Immunotherapy for Colorectal Cancer
Recruiting1 awardPhase 1
Duarte, California
This trial is studying regorafenib in combination with ipilimumab and nivolumab to see if it can help to treat patients with colorectal cancer that has spread and is resistant to chemotherapy.
Trials for DMMR Positive Patients
PD-1 Inhibitor
Dostarlimab for Colon Cancer
Recruiting2 awardsPhase 3
Tucson, Arizona
This trial is testing dostarlimab, a drug that helps the immune system fight cancer. It targets patients with a specific type of colon cancer that has certain genetic features and can be surgically removed. Dostarlimab works by helping the immune system recognize and destroy cancer cells.
Chemotherapy
Chemotherapy + Atezolizumab for Colon Cancer
Recruiting2 awardsPhase 3
Anchorage, Alaska
This trial is testing whether adding atezolizumab to standard chemotherapy works better than chemotherapy alone for patients with stage III colon cancer who have a specific genetic defect. The chemotherapy drugs aim to kill cancer cells, while atezolizumab helps the immune system attack the cancer. Researchers hope this combination will improve survival rates and quality of life for these patients.
PD-1 Inhibitor
Dostarlimab for Colon Cancer
Recruiting2 awardsPhase 2
Iowa City, Iowa
This trial is testing the immunotherapy drug dostarlimab in patients with Stage II and III colon cancer. The goal is to see if the drug can shrink the tumors enough to avoid surgery. Dostarlimab helps the immune system attack the cancer cells.
Phase 3 Trials
PD-1 Inhibitor
Dostarlimab for Colon Cancer
Recruiting2 awardsPhase 3
Tucson, Arizona
This trial is testing dostarlimab, a drug that helps the immune system fight cancer. It targets patients with a specific type of colon cancer that has certain genetic features and can be surgically removed. Dostarlimab works by helping the immune system recognize and destroy cancer cells.
Chemotherapy
ctDNA Testing for Colon Cancer Treatment Prediction
Recruiting1 awardPhase 2 & 3
Pittsburgh, Pennsylvania
This trial tests how well ctDNA testing in the blood predicts treatment for patients with stage IIA colon cancer after surgery. ctDNA are circulating tumor cells that are shed by tumors into the blood. Finding ctDNA in the blood means that there is very likely some small amounts of cancer that remain after surgery. However, this cancer, if detected, cannot be found on other tests usually used to find cancer, as it is too small. Testing for ctDNA levels may help identify patients with colon cancer after surgery who do benefit, and those who do not benefit, from receiving chemotherapy.
Trials With No Placebo
PD-1 Inhibitor
Dostarlimab for Colon Cancer
Recruiting2 awardsPhase 3
Tucson, Arizona
This trial is testing dostarlimab, a drug that helps the immune system fight cancer. It targets patients with a specific type of colon cancer that has certain genetic features and can be surgically removed. Dostarlimab works by helping the immune system recognize and destroy cancer cells.
CDK4/6 Inhibitor
Palbociclib + Cetuximab for Colon Cancer
Recruiting1 awardPhase 2
Chapel Hill, North Carolina
This trial is testing a combination of two drugs, cetuximab and palbociclib, to treat patients with advanced colon cancer. The drugs work together to block cancer cell growth and division. The study focuses on patients whose cancer has specific protein characteristics and who have either not been treated with similar drugs before or have developed resistance after initial treatment.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' ā so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back ā in general, verified trials respond to patients within a few days.